Objective-To compare low (0.5 ng/kg/min) and standard dose (2 ng/kg/min) iloprost (a stable carbacyclin analogue of prostacyclin) in patients with Raynaud's phenomenon secondary to connective tissue disorders.
Iloprost is a chemically stable carbacyclin derivative of prostacyclin, which has been shown in previous studies to have immediate and long term benefits in the treatment of Raynaud's phenomenon when compared with placebo7 8 and to be as effective as nifedipine. 9 The precise mechanism by which clinical benefit is produced is unclear. Iloprost produces vasodilatation,'0 inhibition of platelet aggregation," and enhances inherent fibrinolytic potential,'2 13 all of which may contribute to clinical benefit.
The current regimen for both drugs in the treatment of Raynaud's phenomenon is to increase the dose to the maximum tolerated by the patient.7 This, however, can result in unpleasant side effects-for example, nausea, headache, and flushing.
This study aimed at determining whether the efficacy of iloprost is dependent on dose within the range of doses being used clinically in secondary Raynaud's phenomenon and to establish whether longer term benefits are conferred independent of acute vasomotor effects.
Patients and methods
Fifty five patients were enrolled in the study from five centres (Glasgow (24) Of the 55 patients enrolled, 32 had classical progressive systemic sclerosis (American limited cutaneous scleroderma, five mixed connective tissue disease, one rheumatoid arthritis, one Sj6gren's syndrome, and one childhood dermatomyositis. In the remaining four patients no definite diagnosis had been established, but all had abnormal nailfold capillaroscopy and abnormal antibody profiles.
The study was double blind with patients being randomly allocated in parallel groups to the two treatment regimens. Twenty eight received low dose (0-5 ng/kg/min) and 27 standlard dose (2 ng/kg/min) iloprost. Investigators were unaware of the dose being used as different concentrations of iloprost were infused at the same rate. The mean age of the patients and their disease duration were similar in both groups (table 1) .
During an initial two week assessment peiod a diary was kept recording the duration and severity of each Raynaud's attack. Thereafter, patients were admitted to the ward and received three six hour iloprost infusions on consecutive days. Iloprost was aministered intravenously by a peripheral line and regulated by an IVAC pump. Both low and standard dose infusions were started at 10 ml/h and increased every 15 minutes until a maximum of 40 ml/h was reached. If adverse events occurred the infusion rate was reduced by 10 ml/h at 30 minute intervals until side effects settled. An observer was present during the infusion to record the occurrence of side effects.
Patients figure 1) .
Reduction of the frequency of Raynaud's attacks was greater in weeks 5-8 than 1-4 (p=0-016, F test). Reduction in severity of attacks was also greater in the second half of the follow up period (p=0-03, F test). The improvement seen during weeks 5-8 was unlikely to have been due to a rise in the ambient temperature as between weeks 1 and 4 there was no overall change in ambient temperature from baseline and between weeks 5 and 8 there was a small rise of less than 2°C.
The results from the five centres taking part in this study were compared for duration of disease, total duration and frequency of attacks before treatment, and number of patients with skin lesions. No one centre had entered the most severely affected patients by every para- Eighteen patients had active digital skin lesions either on entry to the study or on follow up. Two patients with ulcers were withdrawn from the study owing to lack of effect (one from each treatment group). Both patients received additional treatment and are therefore excluded from analysis of treatment effect on skin lesions. There was a reduction in the total number of skin lesions in both treatment groups (table 3) . tp=0-0018 (paired t test). Significant increase both groups.
Six new lesions occurred in the low dose group compared with three in the standard group.
PATIENTS' SUBJECTIVE OPINIONS
At weeks 4 and 8 after infusion patients were asked whether they thought they had benefited from treatment. Thirty three patients (60%) thought that they had probably or definitely improved at week 4 and 29 (53%) at week 8. More patients receiving the low dose (19/28 (68%)) thought they had derived benefit compared with those receiving the standard dose (11/27 (41%)), though this did not reach significance (p=0 07, x2 test).
SIDE EFFECTS AND DOSE INFUSED
Side effects were reported in nine (32%) patients receiving the low dose compared with 21 (78%) patients in the standard dose group (p=00013, x2 test). Table 4 shows the side effects reported.
Adverse events severe enough to require a reduction in dose occurred in one patient (4%) in the low dose group and in 16 (59%) patients in the standard dose group (p<0001, x2 test). The dose reductions did not seriously compromise the comparison of the two dose regimens in this study, however. As shown in In our study we were interested to confirm that the benefits of iloprost in secondary Raynaud's phenomenon are only in part dependent on an acute vasodilator effect. We showed that by using a low dose, side effects are reduced and the improved ulcer healing and reduction in Raynaud's phenomenon are similar in magnitude and duration to those produced by the standard dose.
The increase in platelet count seen in this study has previously been reported27 with CLI15, 347 a transdermally absorbed prostaglandin E2 analogue, and may reflect decreased platelet activation over the treatment period. The increase in white cell count has not previously been reported, as far as we know, and may simply be a result of decreased white cell adhesion or a shift from a marginated pool to a circulating pool.
In conclusion, we showed that iloprost given in low dose 05 ng/kg/min is an effective treatment for Raynaud's phenomenon and its use is associated with significantly fewer side effects than the standard dose. Furthermore, we showed that both standard and low dose iloprost enhance ulcer healing. These findings therefore suggest that vasodilatation alone has only a small part to play in the mechanism by which iloprost improves Raynaud's phenomenon and certainly cannot explain the sustained improvement seen. 
